Compare SNDA & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDA | ALMR |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1997 | 2026 |
| Metric | SNDA | ALMR |
|---|---|---|
| Price | $39.33 | $28.83 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $35.75 | N/A |
| AVG Volume (30 Days) | ★ 470.1K | 337.3K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $381,141,000.00 | N/A |
| Revenue This Year | $68.73 | N/A |
| Revenue Next Year | $11.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $24.95 | $21.58 |
| 52 Week High | $44.39 | $38.54 |
| Indicator | SNDA | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 44.49 |
| Support Level | $38.01 | $23.69 |
| Resistance Level | $42.24 | $35.74 |
| Average True Range (ATR) | 1.49 | 1.93 |
| MACD | -0.00 | -0.64 |
| Stochastic Oscillator | 49.58 | 0.28 |
Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic services offered by the company at its senior housing communities comprise meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.